Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
PBLS · Why this verdict
Why Parabilis Medicines (PBLS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Parabilis Medicines cannot currently be evaluated on price-based measures due to a missing price feed, and the available fundamentals point to margin compression, insider selling, and below-average quality that argue for caution once trading data is restored.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company shows value-trap signals: operating margin compression to -8.5% alongside 5 insider sell transactions totaling 0.14% of market cap. Bear case | Operating margin should stabilize above -5% and insider transactions should turn neutral or bullish over the next 12 months. | Tripped→Stable |
| CounterMargin compression combined with insider selling in a clinical-stage biotech often reflects cash-runway pressure that a single quarter of improvement would not resolve. | ||
No current price was returned by the upstream data source this run, which the model flags as a hard data-integrity issue preventing any entry, target, or stop calculation. Warnings | Price data should be restored and stay reliably available in subsequent runs over the next 12 months. | →Stable |
| CounterA missing price feed for a single run is often a transient data-vendor issue, but repeated outages could indicate the ticker has been delisted or is otherwise untradeable, which the price gap alone cannot rule out. | ||
The model explicitly flags quality concerns for the business, reflected in a quality score of 2.8. Quality breakdown | Quality score should rise above 4.0 over the next 12 months as flagged concerns are resolved. | →Stable |
| CounterNamed quality concerns in an early-stage biotech typically stem from structural cash burn that is unlikely to reverse quickly. | ||
The risk profile is elevated, with short interest and debt-to-equity components both scoring near the top of the risk scale. Components | Both short interest and debt-to-equity readings should decline meaningfully over the next 12 months. | →Stable |
| CounterFor a speculative biotech, elevated short interest and leverage can compound quickly if a clinical or financing setback occurs, rather than resolving on their own. | ||
The model's key-risk list flags below-average business quality as a standing concern for the name. Key risks | This flag should be removed as quality metrics improve above the model's minimum threshold over the next 12 months. | →Stable |
| CounterBelow-average business quality flags in speculative biotech names often persist until a major pipeline catalyst changes the fundamental picture, which cannot be assumed within 12 months. | ||
The company shows value-trap signals: operating margin compression to -8.5% alongside 5 insider sell transactions totaling 0.14% of market cap.
Tripped→StableBear case
- Expectation
- Operating margin should stabilize above -5% and insider transactions should turn neutral or bullish over the next 12 months.
CounterMargin compression combined with insider selling in a clinical-stage biotech often reflects cash-runway pressure that a single quarter of improvement would not resolve.
No current price was returned by the upstream data source this run, which the model flags as a hard data-integrity issue preventing any entry, target, or stop calculation.
→StableWarnings
- Expectation
- Price data should be restored and stay reliably available in subsequent runs over the next 12 months.
CounterA missing price feed for a single run is often a transient data-vendor issue, but repeated outages could indicate the ticker has been delisted or is otherwise untradeable, which the price gap alone cannot rule out.
The model explicitly flags quality concerns for the business, reflected in a quality score of 2.8.
→StableQuality breakdown
- Expectation
- Quality score should rise above 4.0 over the next 12 months as flagged concerns are resolved.
CounterNamed quality concerns in an early-stage biotech typically stem from structural cash burn that is unlikely to reverse quickly.
The risk profile is elevated, with short interest and debt-to-equity components both scoring near the top of the risk scale.
→StableComponents
- Expectation
- Both short interest and debt-to-equity readings should decline meaningfully over the next 12 months.
CounterFor a speculative biotech, elevated short interest and leverage can compound quickly if a clinical or financing setback occurs, rather than resolving on their own.
The model's key-risk list flags below-average business quality as a standing concern for the name.
→StableKey risks
- Expectation
- This flag should be removed as quality metrics improve above the model's minimum threshold over the next 12 months.
CounterBelow-average business quality flags in speculative biotech names often persist until a major pipeline catalyst changes the fundamental picture, which cannot be assumed within 12 months.
Per-dimension breakdown
Quality
2.8/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.9 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 0.8 |
| OBV | 1.0 |
| MA position | 6.5 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
Sentiment
8.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 9.3 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 44%
Insider
5.0/10data confidence 50%Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.0 |
| support resistance | 5.8 |
| 52w position | 6.9 |
| gap | 5.0 |
Risk (lower is worse)
6.8/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 8.9 |
| days to cover | 9.0 |
| volatility | 0.0 |
| debt equity | 9.1 |
Catalyst
5.0/10data confidence 50%How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- ASYMMETRY:1.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:2.6<4.5
Warning (0)
none
Reward-to-Risk
1.47
Upside
+22.1%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 56 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.6<4.5 outcome against Sentiment at 8.1 and asymmetric R:R of 1.47.
The strongest dimensions are Sentiment at 8.1, Value at 7.5, and Risk (lower is worse) at 6.8; the weakest are Momentum at 2.6, Quality at 2.8, and Peer rank at 4.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.47 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Data Outage Blocks Trade Setup
Trip ifPrice data stays unavailable (null) for at least 2 consecutive runs of the pipeline.
- P2Value Trap Signals Margin And Insider SellingTripped
Trip ifOperating margin falls below -20% or insider selling exceeds $1 million over a rolling 90-day window.
- P3Quality Concerns Flagged
Trip ifQuality score falls below 1.5.
- P4Elevated Leverage And Short Interest Risk
Trip ifDebt-to-equity ratio exceeds 3.0x.
- P5Below Average Business Quality Risk
Trip ifThe below-average business quality flag persists for more than 3 consecutive quarters without an improvement in the quality score.